News | March 19, 2009

Drug Information Association Hosts Conference on Cardiovascular Safety, QT/Arrhythmia Assessment in Drug Development

March 19, 2009 - The Drug Information Association (DIA), in cooperation with the Heart Rhythm Society (HRS) and the FDA, will host Cardiovascular Safety and QT/Arrhythmia Assessment in Drug Development: Optimizing Drug Development Wednesday, April 29 – Friday, May 1 in Bethesda, MD.

Regulatory, industry, and scientific leaders from around the world will convene to discuss the evolution of drug development, cardiac repolarization, and cardiovascular (CV) safety. The conference will present basic concepts related to the collection, analysis, and interpretation of clinical ECG data, taking into consideration the effect of study design and conduct on these parameters. Sessions will also cover strategies to design a program for QT assessment in all stages of clinical trials and best practices for designing, conducting, analyzing, and interpreting data from a thorough QT/QTc study.

Speakers will also address the strategy behind choosing the optimal timing of the thorough QT study, underlying regulatory thinking in terms of QT prolongation and patient safety, relevant clinical, technological, and statistical issues in the assessment of QT/QTc prolongation in clinical trials. The conference will also address emerging concepts and technologies for QT assessment, such as highly automated measurement methods and their potential role.

"This open forum will discuss the new direction in the development of pharmaceutical agents, practical challenges and possible solutions, ways of challenging the current science, and regulatory approaches,” explains Program Chair Philip Sager, M.D., FACC, FHRS, chief medical officer, CardioDx Inc.

DIA serves more than 30,000 professionals in the biotechnology, pharmaceutical and regulatory industries worldwide. Through its domestic and international meetings, training courses, workshops and Webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA, and with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China.

For more information: www.diahome.org

Related Content

Quantum Genomics Enrolls First Patient in QUORUM Phase IIb Study of Firibastat
News | Pharmaceuticals | June 14, 2019
Quantum Genomics announced the enrollment of the first patient in its QUORUM Phase IIb study of its lead clinical...
FDA Grants Priority Review for Vascepa sNDA
News | Pharmaceuticals | May 29, 2019
Amarin Corp. plc announced that its supplemental new drug application (sNDA) for Vascepa (icosapent ethyl) capsules has...
Vascepa Markedly Reduces First, Repeat and Total Cardiovascular Events
News | Pharmaceuticals | March 29, 2019
Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and total ischemic...
Bempedoic Acid Combination Tablet Significantly Lowers LDL-Cholesterol

Image courtesy of Esperion

News | Pharmaceuticals | March 25, 2019
Phase 3 results from Study 2, also known as CLEAR WISDOM, of bempedoic acid were recently presented at the American...
Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Overlay Init